<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01704716</url>
  </required_header>
  <id_info>
    <org_study_id>HR-NBL-1.7 / SIOPEN</org_study_id>
    <nct_id>NCT01704716</nct_id>
  </id_info>
  <brief_title>High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)</brief_title>
  <official_title>High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Anna Kinderkrebsforschung</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Anna Kinderkrebsforschung</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk
      neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified
      &gt; 12 months at diagnosis).

      The protocol consists of a rapid, dose intensive induction chemotherapy (R3 randomisation -
      Rapid COJEC vs modified N7), peripheral blood stem cell harvest, attempted complete excision
      of the primary tumour, myeloablative therapy (BuMel) followed by peripheral blood stem cell
      rescue, radiotherapy to the site of the primary tumour and immunotherapy (R4 randomisation -
      isotretinoin and ch14.18/CHO, with or without aldesleukin (IL-2).

      In the induction phase, all patients with stage 4 neuroblastoma and those with stage 4s
      MYCN-amplified neuroblastoma will be randomised (R3) to Rapid COJEC or modified N7; localised
      patients receive Rapid COJEC (Rapid COJEC is given with G-CSF support based on the results of
      the R0 randomisation running between 2002 and 2005).

      Following induction treatment peripheral blood stem cell harvest (PBSCH) will be performed
      and complete excision of the primary tumour will be attempted.

      Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the
      end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles.

      After Rapid COJEC induction, localised patients will proceed to consolidation. Patients aged
      12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without
      segmental chromosomal alterations (SCA) are thought to have a good prognosis and will stop
      treatment after induction therapy and surgery to the primary tumour.

      Consolidation consists of BuMel MAT (following the results of the R1 randomisation) followed
      by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary
      tumour.

      During the immunotherapy phase, patients will be randomised (R4) to immunotherapy with
      isotretinoin (13-cis-RA) and ch14.18/CHO, with or without aldesleukin (IL-2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this protocol the term high-risk neuroblastoma refers to children with either

        -  disseminated disease (INSS stage 4: about 40 to 50% of all neuroblastoma) over the age
           of one or

        -  INSS stage 2 and 3 disease with amplification of the MycN proto-oncogene

      Between 10% and 20% of children with stage 3 and occasional patients with stage 2 disease are
      characterised by amplification of the MycN gene in their tumours. This biological
      characteristic has clearly been shown to be associated with a greater risk of relapse and
      death from disease progression. These patients may benefit from very aggressive treatment
      and, based on this hypothesis, they are included in this protocol.

        -  Infants (&lt; 12 months at diagnosis) with MYCN amplified tumours are included. Children
           with this type of presentation and age represent the largest neuroblastoma subgroup.
           Their prognosis remains poor in most cases and our ability to predict the clinical
           course and the outcome of the individual patient is modest.

      Primary objectives:

      R0 randomisation: R0 was opened with the study activation in February 2002 and closed in
      November 2005. The randomised use of G-CSF during COJEC induction resulted in the
      recommendation of the prophylactic use of G-CSF to prevent episodes of febrile neutropenia

      R1 randomisation: R1 was opened with the study activation in February 2002 and closed in
      10/2010 following the results showing significant superiority of myeloablative therapy (MAT)
      with busulfan and melphalan over continuous infusion of carboplatin, etoposide and melphalan
      (CEM). BuMel is now the standard MAT.

      R2 randomisation: R2 was activated in November 2006 (13-cis retinoic acid +/- chimeric
      ch14.18/CHO antibody), modified in July 2009 and suspended in August 2013. R2 randomisation
      tested the hypothesis that immunotherapy with chimeric 14.18/CHO and subcutaneous aldesleukin
      (IL-2, Proleukin®), following MAT and autologous stem cell transplantation, in addition to
      differentiation therapy with 13-cis retinoic acid, will improve 3-year EFS in patients with
      high-risk neuroblastoma.

      R3 randomisation: R3 was opened in June 2011 and tests the hypothesis that modified N7
      induction regimen will improve the metastatic response rates or event free survival (EFS) as
      compared to Rapid COJEC.

      R4 randomisation: R4 was activated in April 2014. The SIOPEN long term infusion (LTI)
      ch14.18/CHO trial successfully lowered the toxicity profile by prolonging the infusion time
      of the same total ch14.18/CHO antibody dose of 100mg/m² to 10 days of continuous infusion in
      relapsed /refractory patients. Hence the HRNBL1.7/SIOPEN study committee wishes to implement
      this more favourable immunotherapy dosing schedule for the time till the induction question
      R3 is answered and the HRNBL1.7/SIOPEN trial may be closed. Considering the high R2 dropout
      rate of patients unable to receive all immunotherapy cycles in the IL-2 s.c. combination
      treatment arm and not observing this effect in the current SIOPEN LTI trial, it is suggested
      to address the IL-2sc dose in the new R4. Therefore the potential synergistic effect of sc
      IL-2 will be addressed again with 50% of the original s.c. IL-2 dose. The IL-2sc dose will
      hence be reduced to 3 x 106 IU IL-2/m2/day s.c. in the HR-NBL1/SIOPEN R4 amendment instead of
      6 x 106 IU IL-2/m2/day s.c as used in the SIOPEN LTI trial. In the second week of each IT
      course s.c.IL-2 will be given on days 2, 4, 6, 8, 10 in parallel to the ch14.18/CHO ctn
      infusion and not during the first 5 days in week 2 as scheduled in the SIOPEN LTI trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (R1: MAT therapy)</measure>
    <time_frame>Up to three years</time_frame>
    <description>The primary endpoint was the event free survival (EFS) calculated from the date of the first R1 randomisation. The following was considered as event:
disease progression or relapse
death from any cause
second neoplasm
Patients lost to follow up without event were considered at the date of their last follow up evaluation.
R1 has been closed in October 2010 following the results of R1 randomisation showing significant superiority for myeloablative therapy (MAT) with busulfan and melphalan (BuMel) in patients with high risk neuroblastoma over MAT with continuous infusion of carboplatin, etoposide and melphalan (CEM). BuMel is now the standard MAT.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Free Survival (R4: immunotherapy)</measure>
    <time_frame>Up to three years</time_frame>
    <description>R4 randomisation comparing immunotherapy with ch14.18/CHO and 13-cis retinoic acid versus 13-cis retinoic acid alone was activated in November 2006. It was amended in July 2009 and now compares immunotherapy with anti GD2 antibody ch14.18/CHO with or without aldesleukin (IL-2).
The primary endpoint is 3-year event free survival calculated from the date of the second randomisation. The following will be considered as events:
disease progression or relapse
death from any cause
second neoplasm
Patients lost to follow up without event will be censored at the date of their last follow-up evaluation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete metastatic response (R3: Induction therapy)</measure>
    <time_frame>Up to 95 days</time_frame>
    <description>R3 randomisation compares two different induction therapy regimen, Rapid COJEC and modified N7.
Complete metastatic response after induction is defined as:
no skeletal uptake on mIBG
Negative bone marrow aspirates (by cytomorphology) and trephines
Absence of other metastatic sites</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival (R3: Induction therapy)</measure>
    <time_frame>Up to three years</time_frame>
    <description>R3 randomisation compares two different induction therapy regimen, Rapid COJEC and modified N7.
The primary endpoint is event free survival calculated from the date of the R3-randomisation. The following will be calculated as events:
disease progression or relapse
death from any cause
second neoplasm
Patients lost to follow up without event will be censored at the date of their last follow up evaluation</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">2700</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to G-CSF during induction treatment (Rapid COJEC) received a single daily subcutaneous injection of 5 microgram/kg/day G-CSF (filgrastim) beginning 24 hours after the last chemotherapy dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction treatment (COJEC) without filgrastim Patients randomised to Rapid COJEC alone will receive induction Treatment without G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1: BuMel MAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The BuMel MAT regimen consists of oral administration of busulphan and the short i.v. infusion of melphalan.
In July 2007 (amendment 3) oral busulfan was changed to i.v. Busulfan (Busilvex)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1: CEM MAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CEM MAT regimen uses three drugs: the dose of Carboplatin must be based on renal function with a target area under the concentration versus time curve (AUC) of 16.4 mg/ml.min, etoposide 350 mg/m2/course and melphalan 210 mg/m2/course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2: ch14.18/CHO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ch14.18/CHO is given at a dose of 20 mg/m2/day over five days every four weeks for five courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2: ch14.18/CHO plus Aldesleukin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomised to receive ch14.18/CHO plus Aldesleukin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rapid COJEC induction treatment is applied over ten weeks; three different courses are given every ten days:
Course A (given on days 0 and 40): vincristine, carboplatin, and etoposide Course B (given on days 10, 30, 50, and 70): vincristine and cisplatin Course C (given on days 20 and 60): vincristine, etoposide, and cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R3: Modified N7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The modified N7 induction is a dose intense induction chemotherapy regimen including two putatively non cross-resistent drug combinations: high-dose cyclophosphamide plus doxorubicin/vincristine (CAV) and high-dose cisplatin/etoposide (P/E).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R4: cnt inf ch14.18/CHO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R4: cnt inf ch14.18/CHO plus Aldesleukin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ch14.18/CHO is given as continuous Infusion over 10 days at a cumulative dose of 100mg/m2. Patients receive 5 cycles of ch14.18/CHO.
In addition, Aldesleukin is given at a dose of 3 x 10e6 on days 1 to 5 and on days 9, 11, 13, 15, and 17 during ch14.18/CHO infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>given during Rapid COJEC and modified N7 therapy</description>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <arm_group_label>R3: Modified N7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldesleukin</intervention_name>
    <description>Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2</description>
    <arm_group_label>R2: ch14.18/CHO plus Aldesleukin</arm_group_label>
    <arm_group_label>R4: cnt inf ch14.18/CHO plus Aldesleukin</arm_group_label>
    <other_name>Interleukin 2, IL-2, IL2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ch14.18/CHO</intervention_name>
    <description>ch14.18/CHO antibody is given during MRD treatment</description>
    <arm_group_label>R2: ch14.18/CHO</arm_group_label>
    <arm_group_label>R2: ch14.18/CHO plus Aldesleukin</arm_group_label>
    <arm_group_label>R4: cnt inf ch14.18/CHO</arm_group_label>
    <arm_group_label>R4: cnt inf ch14.18/CHO plus Aldesleukin</arm_group_label>
    <other_name>anti GD2 antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)</description>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_label>R1: CEM MAT</arm_group_label>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide is given during Induction Treatment (both R3 randomisation arms)</description>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_label>R1: CEM MAT</arm_group_label>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <arm_group_label>R3: Modified N7</arm_group_label>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin is given during Induction Treatment (both R3 randomisation arms)</description>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <arm_group_label>R3: Modified N7</arm_group_label>
    <other_name>CDDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)</description>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <arm_group_label>R0: COJEC</arm_group_label>
    <arm_group_label>R3: COJEC Induction</arm_group_label>
    <arm_group_label>R3: Modified N7</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin is given during Induction Treatment (R3 arm modified N7)</description>
    <arm_group_label>R3: Modified N7</arm_group_label>
    <other_name>Adriamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>G-CSF is given during Induction Treatment</description>
    <arm_group_label>R0: COJEC plus G-CSF</arm_group_label>
    <other_name>Filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.</description>
    <arm_group_label>R1: BuMel MAT</arm_group_label>
    <other_name>Busilvex</other_name>
    <other_name>Myleran</other_name>
    <other_name>Busulphan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan is given during MAT treatment</description>
    <arm_group_label>R1: BuMel MAT</arm_group_label>
    <arm_group_label>R1: CEM MAT</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Established diagnosis of neuroblastoma according to the International Neuroblastoma
             Staging System (INSS).

               -  Age below 21 years.

               -  High risk neuroblastoma defined as either:

                    1. INSS stage 2, 3, 4, and 4s with MYCN amplification, or

                    2. INSS stage 4 without MYCN amplification aged &gt; 12 months at diagnosis

               -  Patients who have received no previous chemotherapy except for one cycle of
                  etoposide and carboplatin (VP16/Carbo). In this situation patients will receive
                  Rapid COJEC induction and the first Rapid COJEC cycle may be replaced by the
                  first cycle VP16/Carbo (etoposide / carboplatin).

               -  Written informed consent, including agreement of parents or legal guardian for
                  minors, to enter a randomised study if the criteria for randomisation are met.

               -  Tumour cell material available for determination of biological prognostic
                  factors.

               -  Females of childbearing potential must have a negative pregnancy test. Patients
                  of childbearing potential must agree to use an effective birth control method.
                  Female patients who are lactating must agree to stop breast-feeding.

               -  Registration of all eligibility criteria with the data centre within 6 weeks from
                  diagnosis.

               -  Provisional follow up of 5 years.

               -  National and local ethical committee approval.

        Exclusion Criteria:

        Any negative answer concerning the inclusion criteria of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth L Ladenstein, MD, MBA, cPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Anna Kinderkrebsforschung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruth L Ladenstein, MD, MBA, cPM</last_name>
    <phone>0043140470</phone>
    <phone_ext>4750</phone_ext>
    <email>ruth.ladenstein@ccri.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sydney Children's Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Anna Kinderspital</name>
      <address>
        <city>Vienna</city>
        <state>Austra</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Ladenstein, MD, MBA, cPM</last_name>
      <phone>0043140470</phone>
      <phone_ext>4750</phone_ext>
      <email>ruth.ladenstein@ccri.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.-Klinik für Kinder- und Jugendheilkunde Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ.Klinik f. Kinder-u. Jugendheilkunde Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landes- Kinderklinik Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Johanns Spital LKH Salzburg</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires St-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Lüttich</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique de l'Espérance</name>
      <address>
        <city>Montegnee</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National State Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Odense</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Skejby Hospital</name>
      <address>
        <city>Skejby</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital d'Enfants Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Pellegrin</name>
      <address>
        <city>Le Pellerin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopitaux de Marseille La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Trousseau Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital American Memorial Hospital</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU-Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre-CHU Strasbourg</name>
      <address>
        <city>Strasburg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital D'Enfants de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;A&amp;P Kyriakou&quot; Children's Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aghia Sophia Children's Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Madarász Children Hospital Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis University of Budapest</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dublin: OLHSC</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Centre</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center of Israel</name>
      <address>
        <city>Petah Tiqwa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale G. Salesi</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitŕ degli studi di Bari</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Orsola</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale per le Microcitemie</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Cosenza</name>
      <address>
        <city>Cosenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera A. Meyer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Giannina Gaslini</name>
      <address>
        <city>Genua</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedal. Univ. di Modena</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sec. Univ. degli Studi di Napoli - Policlinico</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica di Oncoematologia Pediatrica Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Bambini, Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria di Parma-Oncoematologia Pediatrica</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile Spirito Santo</name>
      <address>
        <city>Pescara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Infermi &quot;</name>
      <address>
        <city>Rimini</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Borgo Roma</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Bambino Gesu</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>O.I.R.M. - S. Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto per l'Infanzia &quot;Burlo Garofolo&quot;</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of North-Norway</name>
      <address>
        <city>Tromso</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Bialystok</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens' Hospital in Chorzów</name>
      <address>
        <city>Chorzów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Cracow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University in Gdansk</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Upper Silesian Centre of Child and Mother's Care</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's University Hospital in Lublin</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Medical Sciences Poznan</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute Mother and Child</name>
      <address>
        <city>Warschau</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wroclaw Medical University</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ipofg-Crl</name>
      <address>
        <city>Lissabon</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital F. D. Roosevelt</name>
      <address>
        <city>Banská Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital Ljubljana</name>
      <address>
        <city>Ljubljana</city>
        <zip>10000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. General de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. de Donostia Ntra. Sra. de Aranzazu</name>
      <address>
        <city>Aranzazu</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d`Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. General de Galicia</name>
      <address>
        <city>Galicia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H . Materno-Infantil Teresa Herrera</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Monteprincipe</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. C. U. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carlos Haya</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil La Fe</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Clinico-Universitario</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Silvia's Children's Hospital</name>
      <address>
        <city>Göteburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Linkoping</name>
      <address>
        <city>Linkoping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aberdeen: Royal Aberdeen Children's Hospital</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's NHS Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leeds: St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liverpool: Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLH University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle: Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nottingham: Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford: John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheffield Children's Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ladenstein R, Valteau-Couanet D, Brock P, Yaniv I, Castel V, Laureys G, Malis J, Papadakis V, Lacerda A, Ruud E, Kogner P, Garami M, Balwierz W, Schroeder H, Beck-Popovic M, Schreier G, Machin D, Pötschger U, Pearson A. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol. 2010 Jul 20;28(21):3516-24. doi: 10.1200/JCO.2009.27.3524. Epub 2010 Jun 21.</citation>
    <PMID>20567002</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2012</study_first_submitted>
  <study_first_submitted_qc>October 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2012</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuroblastoma</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>MAT</keyword>
  <keyword>antibody treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

